2022
Targeted Therapies in the Treatment of Uterine Serous Carcinoma
Tymon-Rosario J, Gorman M, Santin A. Targeted Therapies in the Treatment of Uterine Serous Carcinoma. Current Treatment Options In Oncology 2022, 23: 1804-1817. PMID: 36447064, DOI: 10.1007/s11864-022-01030-7.Peer-Reviewed Original ResearchConceptsUterine serous carcinomaRecurrent diseaseSerous carcinomaTreatment of USCEffective disease-modifying treatmentMolecular classificationAppropriate surgical stagingAddition of trastuzumabCombination of immunotherapySystemic adjuvant treatmentDisease-modifying treatmentsEnrollment of patientsHER2-positive tumorsTyrosine kinase inhibitorsUnmet medical needPersonalized cancer careAntibody-drug conjugatesOpinion statementDespiteSurgical cytoreductionAdjuvant treatmentSurgical stagingDismal prognosisSurvival outcomesTherapeutic optionsCancer care
2013
Early stage uterine serous carcinoma: Management updates and genomic advances
Fader AN, Santin AD, Gehrig PA. Early stage uterine serous carcinoma: Management updates and genomic advances. Gynecologic Oncology 2013, 129: 244-250. PMID: 23321062, DOI: 10.1016/j.ygyno.2013.01.004.Peer-Reviewed Original ResearchConceptsEarly stage uterine serous carcinomaUterine serous carcinomaRisk of recurrenceResidual uterine diseaseTaxane-based chemotherapyEarly-stage diseaseNumber of patientsCancer-related deathHigh recurrence rateOptimal management approachHER2/neuPotential therapeutic targetAvailable literaturePIK3CA/Adjuvant therapyCervical involvementStage diseaseBiologic therapyProspective trialEndometrial cancerProspective studyRecurrence rateSerous carcinomaSurvival outcomesAggressive subtype